Six‐month follow‐up of ARIA‐H and iron deposition in real‐world lecanemab therapy for Alzheimer's disease: Evidence from a Chinese 7T MRI cohort
Alzheimer's & Dementia · 2026
DOI: 10.1002/alz.71044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Weiwei Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Magnetic Resonance Imaging, Iron, Brain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, STI2030-Major Projects, the National Key R&D Program of China.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION With the approval of lecanemab for treating Alzheimer's disease (AD), there is an urgent need to evaluate its safety and treatment effects on biomarkers in real‐world practice. METHODS Patients receiving lecanemab ( n = 72) underwent routine 3T and 7T magnetic resonance imaging (MRI) for amyloid‐related imaging abnormality (ARIA) monitoring. Longitudinal changes of iron deposition assessed by quantitative susceptibility mapping (QSM) and its association with plasma biomarkers were further evaluated. RESULTS With use of 7T MRI, we identified characteristic perivascular features and detected ARIA with hemorrhages/hemosiderin deposition (ARIA‐H) ≈4 months earlier than with 3T. QSM detected post‐treatment regional susceptibility reductions. Decreased susceptibility in the temporal, frontal lobes, and the thalamus was associated with plasma amyloid beta 42 (Aβ42) and tau phosphorylated at threonine 217 (p‐tau217) changes. DISCUSSION 7T MRI provides superior ARIA‐H detection and iron dynamics monitoring, supporting its role in risk stratification and therapy assessment for lecanemab‐treated patients. Iron deposition measured by QSM may serve as a promising neuroimaging marker for amyloid‐targeting treatments. Highlights Using 7T magnetic resonance imaging (MRI), this study for the first time visualized amyloid‐related imaging abnormality with hemorrhages/hemosiderin deposition (ARIA‐H) at a submillimeter resolution, characterized by aggregated, clustered cerebral microbleeds in a perivascular distribution, suggesting overlapping pathology with cerebral amyloid angiopathy. The susceptibility‐weighted imaging sequence on 7T MRI enabled detection of ARIA‐H up to 4 months earlier. Plasma amyloid beta 42 (Aβ42) and tau phosphorylated at threonine 217 (p‐tau 217) levels are sensitive biomarkers for amyloid targeted therapy. Quantitative susceptibility mapping (QSM) analysis demonstrated reduced cortical iron burden post‐treatment, which has significant associations with plasma Aβ42 and p‐tau 217 levels, highlighting QSM‐derived iron quantification as a promising neuroimaging indicator for amyloid‐targeted therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Geriatric Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, Hunan, China.
- Engineering Research Center of Hunan Province in Cognitive Impairment Disorders, Central South University, Changsha, Hunan, China.
Förderung
- National Natural Science Foundation of China
- STI2030-Major Projects
- the National Key R&D Program of China
- the Outstanding Youth Fund of Hunan Provincial Natural Science Foundation
- the Scientific Research Program of FuRong Laboratory
- the Brain Health Youth Fund of Shanghai Medical Innovation & Development Foundation
Zitieren
APA
Zhang, W., Liu, H., Zhang, C., Li, Y., Fang, K., Zhou, Y., Weng, L., Fang, L., Luo, Y., Xiao, H., Zhou, L., Jiao, B., & Shen, L. (2026). Six‐month follow‐up of ARIA‐H and iron deposition in real‐world lecanemab therapy for Alzheimer's disease: Evidence from a Chinese 7T MRI cohort. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71044
Vancouver
Zhang W, Liu H, Zhang C, Li Y, Fang K, Zhou Y, et al. Six‐month follow‐up of ARIA‐H and iron deposition in real‐world lecanemab therapy for Alzheimer's disease: Evidence from a Chinese 7T MRI cohort. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71044
BibTeX
@article{Zhang2026,
author = {Zhang, Weiwei and Liu, Haokun and Zhang, Cong and Li, Yulai and Fang, Keying and Zhou, Yafang and Weng, Ling and Fang, Liangjuan and Luo, Yingying and Xiao, Han and Zhou, Lin and Jiao, Bin and Shen, Lu},
title = {Six‐month follow‐up of ARIA‐H and iron deposition in real‐world lecanemab therapy for Alzheimer's disease: Evidence from a Chinese 7T MRI cohort},
journal = {Alzheimer's & Dementia},
year = {2026},
doi = {10.1002/alz.71044}
}
EUVIMED